H3K27M test information | Resource Path

Information for Physicians

Indications for H3K27M mutation testing

Liquid biopsy confirmation of radiographic diagnosis of diffuse midline glioma, H3K27M variant
Tissue biopsy confirmation of H3K27M mutation when immunohistochemistry not definitive
Liquid biopsy confirmation of H3K27M mutation for clinical trial eligibility
Serial liquid biopsy testing for H3K27M as therapeutic response biomarker in context of clinical trial

H3F3A c.83A>T; K27M (sometimes expressed as p.K28M) samples being accepted during analytic validation
HIST1H3B c.83A>T; K27M (sometimes expressed as p.K28M) samples being accepted during analytic validation
H3F3A c.103G>T;p.G35W anticipated late summer 2019
H3F3A c.103G>A;p.G35R anticipated late summer 2019

Specimen Type	Collection Container	Processing	Minimum Volume
Cerebrospinal Fluid (CSF)	CSF collection kit	Required at collection. See instructions below	1 mL for ddPCR 2-5 mL for NGS
Plasma	Purple Top/EDTA Tube	Required at collection. See instructions below	1 mL minimum
Whole Blood	Streck Cell Free DNA BCT Tube	None	Fill tube completely (~ 8 mL)
FFPE biopsy tissue	Paraffin block or scrolls	None	Two 10-micron scrolls + 1 H&E or digital image of H&E to assess tumor content

For each patient, please complete and send back the ResourcePath Molecular Test Requisition
All materials must be properly packaged and labeled to indicate the general nature of the materials being transported. The laboratory only accepts specimens considered Class B/non-infectious, and should be shipped using a FedEx Clinical Pak or equivalent.
The lab accepts specimens Monday through Friday. For samples collected on a Friday, please place them at the appropriate storage conditions and ship the following Monday using the standard overnight shipping option.

Resourcepath, LLC
45945 Trefoil Lane. Suite 175
Sterling, VA 20166, USA

Please send an email to info@resourcepath.net when the specimens have shipped and include the following information: